Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Reardon

Thoracic Surgery (Cardiothoracic Vascular Surgery) Houston, TX Medical Doctor

NPI 1174523229 CMS profile 53412

6550 Fannin St, Suite 1401, Houston, TX 77030

Open in the dashboard

General payments

$712,859

860 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,998,930 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Reardon of Houston, TX is reported in the CMS Open Payments database as having received $712,859 across 860 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,998,930 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $64,238 112
2024 General $147,945 135
2023 General $130,791 142
2022 General $108,013 148
2021 General $29,599 44
2020 General $51,865 81
2019 General $180,410 198

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Reardon
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Michael Reardon were reported at $64,238. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Michael Reardon Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $180,410 $886 $178–$3,167 $163
2020 $51,865 $341 $108–$1,605 $114
2021 $29,599 $453 $125–$1,886 $132
2022 $108,013 $695 $180–$2,566 $149
2023 $130,791 $745 $205–$2,662 $160
2024 $147,945 $799 $214–$2,967 $164
2025 $64,238 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $417,159 409 payments
  2. Medtronic Vascular, Inc. $174,367 175 payments
  3. Abbott Laboratories $49,771 91 payments
  4. W. L. Gore & Associates, Inc. $28,628 35 payments
  5. Boston Scientific Corporation $24,809 45 payments
  6. Admedus Corporation $8,000 1 payment
  7. Edwards Lifesciences Corporation $4,850 51 payments
  8. Baylis Medical Company Inc $2,500 1 payment
  9. Baxter Healthcare $858 9 payments
  10. Abiomed $513 5 payments
  11. Other $1,404 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $469,993 146 payments
  2. Travel and Lodging $120,257 258 payments
  3. Consulting Fee $73,108 48 payments
  4. Food and Beverage $25,296 397 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $9,000 4 payments
  6. Honoraria $8,575 2 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,000 1 payment
  8. Grant $1,123 2 payments
  9. Long term medical supply or device loan $282 1 payment
  10. Education $225 1 payment
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $347,719 275 payments
  2. CoreValve Evolut Transcatheter Valve Systems $125,619 119 payments
  3. Product in Development $27,408 17 payments
  4. CoreValve Evolut Transcatheter Valve Systems $23,065 23 payments
  5. Avalus Heart Valves $18,261 13 payments
  6. Mitra Clip system $15,241 6 payments
  7. Avalus Heart Valves $12,330 15 payments
  8. NAVITOR Structural Heart $9,341 13 payments
  9. NAVITOR Vascular $6,009 4 payments
  10. PORTICO $5,312 10 payments
  11. Other $27,016 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$109,599

Medicare's payments for the services billed

Medicare patients

142

Average age 77

Services billed

187

62 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 74%
Arthritis 51%
Atrial fibrillation 50%
Chronic kidney disease 47%
Diabetes 42%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

860 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record